Samsung Electronics Co., Ltd.

Yun Jeong Song

Kyung Ah Kim

Yun Ju Jeong

Jae Young Choi

Seung Hyun Lee

Ji Min Lee

Mi Young Cho

Soo Yeon Jung

Saet Byoul Lee

Ho Yeong Song

Seung-Hyun Lee

Kwang Ho Cheong

Hyo Seon Lee

Kwang-ho Cheong

Kyung-Ah Kim

Ji-Min Lee

Young Mi Oh

Jae Hyun Choi

Ji-min Lee

Seon Hui Shim

Mi-young Cho

Hye-Won Park

Geun Woong Kim

Han Na Choi

Hyeon-seok Yoo

Yoon Aa Choi

Yoon-aa Choi

Hye Won Park

Yun-Ju Jeong

Yoon-Aa Choi

Mi-Young Cho

Young-Mi Oh

Jae-Hyun Choi

Saet-Byoul Lee

Ho-Yeong Song

Geu Woong Kim

Geun-Woong Kim

Kwang-Ho Cheong

A biomarker for predicting and/or monitoring the efficacy of a c-Met inhibitor; a composition for predicting and/or monitoring the efficacy of a c-Met inhibitor, comprising a material detecting the biomarker; a composition for selecting a subject suitable for the application of a c-Met inhibitor, comprising a material detecting the biomarker; a method for predicting and/or monitoring the efficacy of a c-Met inhibitor using the biomarker; a method for selecting a subject suitable for the application of a c-Met inhibitor using the biomarker; and a method for preventing and/or treating cancer comprising administering a c-Met inhibitor to the selected subject.

Method for predicting efficacy of c-Met inhibitor

Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-Met antibody, the use of the anti-idiotype antibody for detecting the anti-c-Met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto.

Anti-idiotype antibody against anti-c-MET antibody

Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient.

Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases

A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.

Method of combination therapy using an anti-C-Met antibody

There are provided a fusion protein formed by coupling of anti-c-Met antibody and VEGF-binding fragment, a bispecific antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, a pharmaceutical composition comprising the bispecific antibody as an active ingredient, and a method for preparing the bispecific antibody which is targeted at c-Met and VEGF at the same time, with improved anticancer and anti-angiogenesis effects, comprising coupling an anti-c-Met antibody with a VEGF-binding fragment.

Fusion protein comprising anti-c-Met antibody and VEGF-binding fragment

Growing community of inventors

Seongnam-si, South Korea

Yun Jeong Song